Medgenome

Medgenome

Promoter: Sam Santhosh
Website: www.medgenome.com
Our Involvement: Invested in Nov 2013

MedGenome aims to be the leading provider of personalized, preventive, predictive & specialized molecular diagnostics (MDx) services in Emerging Markets (starting with India) leveraging next generation sequencing (NGS) technologies.

Most diagnostics are currently based on traditional diagnostic methods leading to late stage detection of diseases resulting in increased impact of diseases & cost of treatment. MedGenome provides reliable molecular genetic tests for accurate disease diagnosis, improved risk assessment & enhanced quality of life through personalized therapy. Over time, it also aims to be a cost effective R&D (4x-6x cheaper than current price for gene testing) & proprietary data provider for developed markets by assisting pharmaceutical companies with commercial & government funded exploratory research, drug discovery, diagnostics tests, analytical & reporting tool.

Comments are closed.